A critical role for c‐Myc in group 2 innate lymphoid cell activation
Autor: | Dale D. Tang, Shanti S. D’Souza, Ivan Ting Hin Fung, Jiexue Pan, Qi Yang, Yinna Wang, Mingwei Liang, Longyun Ye, Xiaofei Shen, Muhammad Asghar Pasha, Gargi Patel |
---|---|
Rok vydání: | 2020 |
Předmět: |
Immunology
Biology Article Proto-Oncogene Proteins c-myc Mice Gene expression medicine Animals Humans Immunology and Allergy Lymphocytes Lung STAT6 Mice Knockout Interleukin-13 Cell growth Effector Microarray analysis techniques Innate lymphoid cell Interleukin-33 medicine.disease Asthma Immunity Innate respiratory tract diseases Bronchial hyperresponsiveness Cytokines Chromatin immunoprecipitation |
Zdroj: | Allergy |
ISSN: | 1398-9995 0105-4538 |
DOI: | 10.1111/all.14149 |
Popis: | Background Asthma is a complicated chronic inflammatory disorder characterized by airway inflammation and bronchial hyperresponsiveness. Group 2 innate lymphoid cells (ILC2) are tissue-resident innate effector cells that can mediate airway inflammation and hyperresponsiveness through production of IL-5, IL-13 and VEGFA. ILC2 in asthma patients exhibit an activated phenotype. However, molecular pathways that control ILC2 activation are not well understood. Methods MYC expression was examined in ILC2 sorted from peripheral blood of healthy controls and asthma patients or cultured with or without activating cytokines. CRISPR knockout technique was used to delete c-Myc in primary murine lung ILC2 or an ILC2 cell line. Cell proliferation was examined, gene expression pattern was profiled by genome-wide microarray analysis, and direct gene targets were identified by Chromatin immunoprecipitation (ChIP). ILC2 responses, airway inflammation and airway hyperresponsiveness were examined in Balb/c mice challenged with Alternaria extracts, with or without treatment with JQ1. Results ILC2 from asthma patients expressed increased amounts of MYC. Deletion of c-Myc in ILC2 results in reduced proliferation, decreased cytokine production, and reduced expression of many lymphocyte activation genes. ChIP identified Stat6 as a direct gene target of c-Myc in ILC2. In vivo inhibition of c-Myc by JQ1 treatment repressed ILC2 activity and suppressed Alternaria-induced airway inflammation and AHR. Conclusion c-Myc expression is upregulated during ILC2 activation. c-Myc is essential for ILC2 activation and their in vivo pathogenic effects. These findings suggest that targeting c-Myc may unlock novel strategies to combat asthma or asthma exacerbation. |
Databáze: | OpenAIRE |
Externí odkaz: |